Clinical Trial Update: Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing cognitive outcomes in relapsing-remitting multiple sclerosis patients treated with BG00012 (dimethyl fumarate) by Biogen has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED